EP1392293A4 - PROCESS FOR THE TREATMENT OF TUMORS BASED ON NORDIHYDROGUAIARETIC ACID DERIVATIVES - Google Patents

PROCESS FOR THE TREATMENT OF TUMORS BASED ON NORDIHYDROGUAIARETIC ACID DERIVATIVES

Info

Publication number: EP1392293A4
Authority: EP; European Patent Office
Prior art keywords: treatment; acid derivatives; nordihydroguaiaretic acid; tumors based; tumors
Prior art date: 2001-05-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP02739227A

Other languages

German (de)

French (fr)

Other versions

EP1392293A1 (en

EP1392293B1 (en

Inventor

Ru Chih C Huang

Jonathan D Heller

Chih-Chuan Chang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-09

Filing date

2002-05-08

Publication date

2005-05-25

2002-05-08 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

2004-03-03 Publication of EP1392293A1 publication Critical patent/EP1392293A1/en

2005-05-25 Publication of EP1392293A4 publication Critical patent/EP1392293A4/en

2016-10-26 Application granted granted Critical

2016-10-26 Publication of EP1392293B1 publication Critical patent/EP1392293B1/en

2022-05-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP02739227.3A 2001-05-09 2002-05-08 Method for treatment of tumors using nordihydroguaiaretic acid derivatives Expired - Lifetime EP1392293B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/851,425 US6608108B2 (en)	1999-10-15	2001-05-09	Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US851425		2001-05-09
PCT/US2002/014374 WO2002089795A1 (en)	2001-05-09	2002-05-08	Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Publications (3)

Publication Number	Publication Date
EP1392293A1 EP1392293A1 (en)	2004-03-03
EP1392293A4 true EP1392293A4 (en)	2005-05-25
EP1392293B1 EP1392293B1 (en)	2016-10-26

Family

ID=25310742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02739227.3A Expired - Lifetime EP1392293B1 (en)	2001-05-09	2002-05-08	Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Country Status (8)

Country	Link
US (3)	US6608108B2 (en)
EP (1)	EP1392293B1 (en)
JP (2)	JP2004534025A (en)
CN (1)	CN1525857B (en)
AU (1)	AU2002311890C1 (en)
CA (1)	CA2447045A1 (en)
SG (1)	SG169224A1 (en)
WO (1)	WO2002089795A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6365787B1 (en) *	1994-09-30	2002-04-02	The Johns Hopkins University	Compounds for the suppression of HIV TAT transactivation
US6608108B2 (en) *	1999-10-15	2003-08-19	Johns Hopkins University	Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US7728036B2 (en)	2003-05-20	2010-06-01	Erimos Pharmaceuticals, Llc	Methods for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) *	2003-05-20	2006-06-29	Erimos Pharmaceuticals Llc	Methods and compositions for delivery of catecholic butanes for treatment of diseases
AU2004249124A1 (en) *	2003-05-20	2004-12-29	Erimos Pharmaceuticals Llc	Methods and compositions for delivery of catecholic butanes for treatment of diseases
EP2241572A3 (en)	2003-06-03	2011-04-06	Eli Lilly And Company	Modulation of survivin expression
US20060019972A1 (en) *	2004-04-27	2006-01-26	California Institute Of Technology	Methods of treating cancer by inhibiting histone gene expression
CN100440843C (en) *	2004-05-12	2008-12-03	华为技术有限公司	Ring net and method for realizing service
US8440648B2 (en) *	2004-07-20	2013-05-14	Erimos Pharmaceuticals Llc	Methods and compositions for treatment of intraepithelial neoplasia
AU2005319166A1 (en) *	2004-12-22	2006-06-29	The Gillette Company	Reduction of hair growth with survivin inhibitors
CA2595617C (en) *	2005-01-27	2014-06-03	Erimos Pharmaceuticals Llc	Formulations for injection of catecholic butanes, including ndga compounds, into animals
CN101150955B (en) *	2005-01-27	2013-04-17	埃里莫斯医药品有限公司	Oral formulations for delivery of catecholic butanes including NDGA compounds
US20060276423A1 (en) *	2005-04-18	2006-12-07	Rachel Altura	Survivin-directed RNA interference-compositions and methods
US8367126B2 (en)	2005-09-27	2013-02-05	University Of Kentucky Research Foundation	Berry preparations and extracts
US7964223B2 (en) *	2005-09-27	2011-06-21	University Of Kentucky Research Foundation	Berry preparations and extracts
US20090155349A1 (en) *	2006-02-23	2009-06-18	Jonathan Daniel Heller	Methods of treating influenza viral infections
US20100047371A1 (en) *	2006-08-29	2010-02-25	Mumper Russell J	Compositions and methods for oral cancer chemoprevention using berry preparations and extracts
ES2476249T3 (en) *	2006-10-02	2014-07-14	Erimos Pharmaceuticals Llc	NDGA derivatives tetrasubstituted by means of ether bonds and carbamates bonds and their synthesis and pharmaceutical uses
US9067875B2 (en)	2006-10-02	2015-06-30	Erimos Pharmaceuticals Llc	Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US20100093872A1 (en) *	2008-10-15	2010-04-15	Erimos Pharmaceuticals Llc	Stable aqueous formulations of water insoluble or poorly soluble drugs
CN101690829B (en) *	2009-08-31	2013-09-18	中国科学院上海硅酸盐研究所	Method for preparing re-cellularized biological valve material
US20120171213A1 (en)	2009-09-10	2012-07-05	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of treating tumors
MX2013008833A (en)	2011-02-02	2013-12-06	Amgen Inc	Methods and compositons relating to inhibition of igf-1r.
CA2832860A1 (en) *	2011-04-21	2012-10-26	Children's Hospital Medical Center	Therapy for leukemia
US10342767B2 (en)	2011-04-21	2019-07-09	Children's Hospital Medical Center	Therapy for kinase-dependent malignancies
EP2776042B1 (en)	2011-11-11	2019-03-20	Duke University	Combination drug therapy for the treatment of solid tumors
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
CN105764502A (en)	2013-07-26	2016-07-13	现代化制药公司	Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
MY192978A (en)	2015-06-22	2022-09-20	Janssen Biotech Inc	Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
WO2017129763A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
MX391317B (en)	2017-02-17	2025-03-21	Promotora Tecnica Ind S A De C V	IMPROVED COMPOSITION BASED ON NORHYDROGUAYARETIC ACID.
EP4065108A4 (en)	2019-11-25	2023-12-20	The Johns Hopkins University	FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE FOR STIMULATING HUMORAL IMMUNITY IN TUMORS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5008294A (en)	1985-02-11	1991-04-16	Chemex Pharmaceuticals, Inc.	Methods of treating tumors with compositions of catecholic butanes
US5276060A (en) *	1979-06-19	1994-01-04	Block/Chemex, G.P.	Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (en)	1980-03-13	1981-09-24	Henkel KGaA, 4000 Düsseldorf	DESODORING COSMETIC COMPOSITIONS
US4774229A (en) *	1982-04-05	1988-09-27	Chemex Pharmaceuticals, Inc.	Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4708964A (en)	1984-02-09	1987-11-24	Chemex Pharmaceuticals	Lipoxygenase inhibitors
US4880637A (en)	1985-02-11	1989-11-14	Chemex Pharmaceuticals, Inc.	Compositions of catecholic butanes with zinc
WO1988001509A1 (en) *	1986-08-25	1988-03-10	Chemex Pharmaceuticals, Inc.	Pharmacologically active compositions of catecholic butanes with zinc
US5559149A (en)	1990-01-29	1996-09-24	Johnson & Johnson Consumer Products, Inc.	Skin care compositions containing retinoids
US5646186A (en)	1994-05-17	1997-07-08	Johnson & Johnson Consumer Products, Inc.	Retinoid composition
US5409690A (en) *	1993-06-23	1995-04-25	Chemex Pharmaceuticals, Inc.	Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en)	1994-09-30	2002-04-02	The Johns Hopkins University	Compounds for the suppression of HIV TAT transactivation
US6071949A (en) *	1995-03-14	2000-06-06	The United States Of America As Represented By The Department Of Health And Human Services	Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en)	1996-07-01	1998-11-17	Larreacorp, Ltd.	Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en)	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
ATE414149T1 (en) *	1996-11-20	2008-11-15	Univ Yale	SURVIVIN, A PROTEIN THAT INHIBITS CELLULAR APOPTOSIS AND ITS MODULATION
US6077709A (en) *	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6608108B2 (en) *	1999-10-15	2003-08-19	Johns Hopkins University	Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) *	1999-10-15	2001-04-10	John Hopkins University	Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

2001
- 2001-05-09 US US09/851,425 patent/US6608108B2/en not_active Expired - Lifetime
2002
- 2002-05-08 CA CA002447045A patent/CA2447045A1/en not_active Withdrawn
- 2002-05-08 AU AU2002311890A patent/AU2002311890C1/en not_active Ceased
- 2002-05-08 CN CN028138627A patent/CN1525857B/en not_active Expired - Lifetime
- 2002-05-08 JP JP2002586930A patent/JP2004534025A/en active Pending
- 2002-05-08 WO PCT/US2002/014374 patent/WO2002089795A1/en active Application Filing
- 2002-05-08 EP EP02739227.3A patent/EP1392293B1/en not_active Expired - Lifetime
- 2002-05-08 SG SG200507965-2A patent/SG169224A1/en unknown
- 2002-10-15 US US10/270,313 patent/US6777444B2/en not_active Expired - Lifetime
2003
- 2003-12-16 US US10/735,910 patent/US8318815B2/en not_active Expired - Fee Related
2009
- 2009-07-29 JP JP2009177106A patent/JP2009242438A/en active Pending

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.D.HELLER ET ALL.: "Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo", CANCER RESEARCH, vol. 61, 15 July 2001 (2001-07-15), pages 5499 - 5504, XP002322391 *
JOSHUA D. LAMBERT ET ALL.: "Tetra-O-Methylnordihydroguaiaretic acid inhibits melanoma in vivo", CANCER LETTERS, vol. 171, 28 August 2001 (2001-08-28), pages 47 - 56, XP002322390 *
See also references of WO02089795A1 *

Also Published As

Publication number	Publication date
CN1525857A (en)	2004-09-01
US20030171416A1 (en)	2003-09-11
CA2447045A1 (en)	2002-11-14
US6608108B2 (en)	2003-08-19
EP1392293A1 (en)	2004-03-03
WO2002089795A1 (en)	2002-11-14
SG169224A1 (en)	2011-03-30
AU2002311890C1 (en)	2008-05-15
AU2002311890B2 (en)	2007-07-26
US20040127562A1 (en)	2004-07-01
CN1525857B (en)	2013-06-12
JP2004534025A (en)	2004-11-11
JP2009242438A (en)	2009-10-22
US20020065310A1 (en)	2002-05-30
US6777444B2 (en)	2004-08-17
US8318815B2 (en)	2012-11-27
EP1392293B1 (en)	2016-10-26

Publication	Publication Date	Title
EP1392293A4 (en)	2005-05-25	PROCESS FOR THE TREATMENT OF TUMORS BASED ON NORDIHYDROGUAIARETIC ACID DERIVATIVES
ATE455106T1 (en)	2010-01-15	ACYL DERIVATIVES FOR THE TREATMENT OF VLA-4 RELATED DISEASES
EE200200716A (en)	2004-08-16	Compounds for the Treatment of Alzheimer's Disease
EP1416052A4 (en)	2005-10-12	PROCESS FOR THE PRODUCTION OF 1,4-DIHYDROXY-2-NAPHTHOTIC ACID
DE50214494D1 (en)	2010-07-29	DEVICE FOR THE INTERMITTENT OCCLUSION OF THE KORONARSINUS
DE60218493D1 (en)	2007-04-12	SUBSTITUTED 7-AZA-Ä2.2.1ÜBICYCLOHEPTANE FOR THE TREATMENT OF DISEASES
MA26992A1 (en)	2004-12-20	PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
MA25223A1 (en)	2001-07-02	PROCESS FOR THE PREPARATION OF 4-CARBOXY-AMINO-2-SUBSTITUE-1,2,3,4 TETRAHYDROQUINOLEINE
FR2846651B1 (en)	2006-06-16	PROCESS FOR PRODUCING CARBOXYLIC ACIDS
EP1484406A4 (en)	2005-07-27	PROCESS FOR PRODUCING N-ACETYLNEURAMINE ACID
FR2831171B1 (en)	2007-02-02	PROCESS FOR PREPARING POLY-OR COPOLY-GLUCURONIC ACID
FR2818979B1 (en)	2003-05-30	PROCESS FOR THE PREPARATION OF IMIDACLOPRIDE
FR2833596B1 (en)	2005-02-18	PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES
FR2791673B1 (en)	2001-06-08	PROCESS FOR THE PREPARATION OF ESTERS OF HYDROXYMETHYLTHIOBUTYRIC ACID
FR2818638B1 (en)	2003-02-07	PROCESS FOR THE PREPARATION OF CARBOXYLIC ACIDS BY PALLADIUM CARBONYLATION
FR2829134B1 (en)	2006-11-24	PROCESS FOR THE PREPARATION OF ALKYLIMIDAZOLIDONE (METH) ACRYLATES
MA24831A1 (en)	1999-12-31	PROCESS FOR THE PREPARATION OF HYDROXAMIC ACIDS
FR2835832B1 (en)	2004-03-19	PROCESS FOR THE OLIGOMERIZATION OF LACTIC ACID
FR2818639B1 (en)	2003-02-07	IMPROVED PROCESS FOR THE MANUFACTURE OF UNSATURATED CARBOXYL ESTERS
FR2826364B1 (en)	2005-01-14	PROCESS FOR THE HEMIHYDROGENATION OF DINITRILES OF AMINONITRILES
IT1307976B1 (en)	2001-11-29	PROCESS FOR THE PREPARATION OF BENZOPHENONSOLPHONIC ACIDS.
EP1295864A4 (en)	2005-12-28	PROCESS FOR THE PREPARATION OF 1,5-DIAMINONAPHTALENES
FR2791668B1 (en)	2001-05-04	PROCESS FOR THE PREPARATION OF BETA-HYDROXY ACIDS
FR2807041B1 (en)	2002-11-29	SEMI-CONTINUOUS PROCESS FOR THE PREPARATION OF BIS-SILYL CARBOXYLIC ACID AMIDES
FR2829152B1 (en)	2004-09-10	ENZYMATIC PROCESS FOR THE ENANTIOMERIC RESOLUTION OF AMINO ACIDS

Legal Events

Date	Code	Title	Description
2004-01-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-03-03	17P	Request for examination filed	Effective date: 20031203
2004-03-03	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2004-03-03	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-11-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1062635 Country of ref document: HK
2005-05-25	A4	Supplementary search report drawn up and despatched	Effective date: 20050412
2006-10-25	17Q	First examination report despatched	Effective date: 20060920
2016-04-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 60248438 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031417000 Ipc: A61P0035020000
2016-05-05	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2016-05-25	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/075 20060101ALI20160415BHEP Ipc: A61K 31/405 20060101ALI20160415BHEP Ipc: A61P 35/02 20060101AFI20160415BHEP Ipc: A61K 31/198 20060101ALI20160415BHEP Ipc: A61K 31/417 20060101ALI20160415BHEP Ipc: A61K 31/225 20060101ALI20160415BHEP Ipc: A61K 31/401 20060101ALI20160415BHEP
2016-06-01	INTG	Intention to grant announced	Effective date: 20160506
2016-09-19	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-09-23	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-10-26	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2016-10-26	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-11-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 60248438 Country of ref document: DE Owner name: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, US Free format text: FORMER OWNER: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US
2016-11-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 839597 Country of ref document: AT Kind code of ref document: T Effective date: 20161115
2016-11-16	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-12-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 60248438 Country of ref document: DE
2017-03-01	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20161026
2017-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 839597 Country of ref document: AT Kind code of ref document: T Effective date: 20161026
2017-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170127
2017-05-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170227
2017-06-20	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 60248438 Country of ref document: DE Representative=s name: LEINWEBER & ZIMMERMANN, DE Ref country code: DE Ref legal event code: R082 Ref document number: 60248438 Country of ref document: DE Representative=s name: LEINWEBER & ZIMMERMANN PATENTANWALTS-PARTG MBB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 60248438 Country of ref document: DE Owner name: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, US Free format text: FORMER OWNER: JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US
2017-07-19	REG	Reference to a national code	Ref country code: GB Ref legal event code: S117 Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 26 MAY 2017
2017-07-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 60248438 Country of ref document: DE
2017-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531
2017-09-01	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2017-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2017-10-04	26N	No opposition filed	Effective date: 20170727
2017-12-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2018-01-12	REG	Reference to a national code	Ref country code: FR Ref legal event code: RM Effective date: 20171208
2018-01-26	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1062635 Country of ref document: HK
2018-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026
2018-02-21	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2018-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531
2018-03-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170508
2018-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170508
2018-05-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161026
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026
2021-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20210527 Year of fee payment: 20 Ref country code: FR Payment date: 20210525 Year of fee payment: 20
2021-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20210527 Year of fee payment: 20
2022-05-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 60248438 Country of ref document: DE
2022-06-01	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20220507
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220507